Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Stock analysts at Jefferies Group upped their FY2017 earnings per share estimates for shares of Alnylam Pharmaceuticals in a report issued on Monday. Jefferies Group analyst M. Raycroft now expects that the biopharmaceutical company will earn ($5.39) per share for the year, up from their previous forecast of ($5.49). Jefferies Group currently has a “Buy” rating and a $130.00 price target on the stock. Jefferies Group also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.32) EPS, FY2018 earnings at ($5.70) EPS, FY2019 earnings at ($3.91) EPS, FY2020 earnings at ($1.71) EPS and FY2021 earnings at $1.41 EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The business had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.21) earnings per share.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $128.60 on Wednesday. The firm has a market capitalization of $12,650.00, a P/E ratio of -24.50 and a beta of 2.98. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a 1-year low of $35.98 and a 1-year high of $147.63.
A number of hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio boosted its position in Alnylam Pharmaceuticals by 3.2% in the third quarter. Public Employees Retirement System of Ohio now owns 32,880 shares of the biopharmaceutical company’s stock worth $3,863,000 after purchasing an additional 1,026 shares during the last quarter. Security National Bank of SO Dak purchased a new position in Alnylam Pharmaceuticals in the third quarter worth $247,000. California Public Employees Retirement System boosted its position in Alnylam Pharmaceuticals by 5.1% in the third quarter. California Public Employees Retirement System now owns 133,206 shares of the biopharmaceutical company’s stock worth $15,650,000 after purchasing an additional 6,506 shares during the last quarter. Virtu Financial LLC purchased a new position in Alnylam Pharmaceuticals in the third quarter worth $286,000. Finally, Orbimed Advisors LLC boosted its position in Alnylam Pharmaceuticals by 69.7% in the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after purchasing an additional 445,600 shares during the last quarter. 88.39% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Dennis A. Ausiello sold 20,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $130.00, for a total transaction of $2,600,000.00. Following the completion of the sale, the director now owns 20,000 shares in the company, valued at $2,600,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the company’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $121.46, for a total value of $4,089,072.36. Following the sale, the executive vice president now owns 45,201 shares of the company’s stock, valued at approximately $5,490,113.46. The disclosure for this sale can be found here. Insiders have sold 274,075 shares of company stock valued at $35,356,089 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.